Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation

Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-κB signaling

(2017) Yandong Lu et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Role of STAT3 Phosphorylation in Ethanol-Mediated Proliferation of Breast Cancer Cells

(2016) Poornima devi Narayanan et al.   Journal of Breast Cancer

Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

(2016) Changro Lee et al.   Journal of Breast Cancer

Sinapine reverses multi-drug resistance in MCF-7/dox cancer cells by downregulating FGFR4/FRS2α-ERK1/2 pathway-mediated NF-κB activation

(2016) Ying Guo et al.   PHYTOMEDICINE

Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells

(2015) Fei Zhang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling

(2015) Yuan-Zheng Xia et al.   PHYTOMEDICINE

Chronic inflammation up-regulates P-gp in peripheral mononuclear blood cells via the STAT3/Nf-κb pathway in 2,4,6-trinitrobenzene sulfonic acid-induced colitis mice

(2015) Jiali Liu et al.   Scientific Reports

Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance

(2014) Oliver Bruhn et al.   Expert Opinion on Drug Metabolism & Toxicology

Dioscin Restores the Activity of the Anticancer Agent Adriamycin in Multidrug-Resistant Human Leukemia K562/Adriamycin Cells by Down-Regulating MDR1 via a Mechanism Involving NF-κB Signaling Inhibition

(2013) Lijuan Wang et al.   JOURNAL OF NATURAL PRODUCTS

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

(2012) Sidong Huang et al.   CELL

Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1

(2012) Jean-Pierre Gillet et al.   DRUG RESISTANCE UPDATES

New targets and approaches in osteosarcoma

(2012) Jonathan Gill et al.   PHARMACOLOGY & THERAPEUTICS

The Challenge of Exploiting ABCG2 in the Clinic

(2011) Robert W. Robey et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

STAT3 SIGNALING: Anticancer Strategies and Challenges

(2011) P. A. Johnston et al.   MOLECULAR INTERVENTIONS

L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines

(2009) Ling-Yen Chiu et al.   TOXICOLOGY LETTERS

Imatinib resistance in multidrug-resistant K562 human leukemic cells

(2008) Yanina Assef et al.   LEUKEMIA RESEARCH